Angion Biomedica Corp (ANGN) News
Filter ANGN News Items
ANGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ANGN News From Around the Web
Below are the latest news stories about ANGION BIOMEDICA CORP that investors may wish to consider to help them evaluate ANGN as an investment opportunity.
Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite RiskyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Angion (ANGN) Down on Merger Agreement With Private BiotechAngion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off Tuesday with a look at the biggest pre-market stock movers that traders will want to keep an eye on today! |
Elicio Therapeutics and Angion Enter into Definitive Merger AgreementMerger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern Time on Wednesday, January 18 BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLO |
Bullish insiders bet US$857k on Angion Biomedica Corp. (NASDAQ:ANGN)Multiple insiders secured a larger position in Angion Biomedica Corp. ( NASDAQ:ANGN ) shares over the last 12 months... |
Angion Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsUNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that on December 15, 2022, it received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30 consecutive business days the bid price of Angion’s common stock had closed bel |
Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority ReviewThe FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023. |
BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA FilingThe FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox. |
Imago (IMGO) Shares Surge 104% on Buyout Offer From MerckImago BioSciences (IMGO) to be acquired by pharma-giant Merck (MRK) for $1.35 billion. The transaction is likely to close by first-quarter 2023. |
Apellis (APLS) Rises on FDA Acceptance of NDA Amendment for GAThe FDA accepts Apellis' (APLS) major amendment to the NDA for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration. A decision is now due on Feb 26, 2023. Stock up. |